The biotechnology industry is characterized by high risk and high reward. Fraught with instability and uncertainty, biotechnology reflects the often-unpredictable nature of the underlying science.

Capital market investors, excited by the possibilities of blockbuster biotechnology products, remain increasingly skeptical of the daunting development, regulatory, insurance and financing risks. Intellectual property protection of biotechnology faces historic, new limitations and difficulties. The regulatory burden is forever increasing, and reimbursement has become a dominant consideration for drug development investors.

You need experienced lawyers who are committed to guiding you through a wide range of legal matters. Dentons eases the pressures you face; our multidisciplinary team of lawyers are scientifically savvy and driven to deliver innovative solutions. Many of our lawyers have advanced degrees in biotechnology-related disciplines. Others have relevant financial skills or knowledge of intellectual property matters. All of us bring skills and experience to work with you to determine your needs and meet them. By identifying and solving your biotechnology legal issues, we improve your focus on areas that attracted you to the sector—whether discovery, research, product development, business development or commercialization. Look to Dentons for innovative business and legal solutions across the biotechnology sector, including:

• Clinical trial management
• Collaboration agreements
• Corporate governance
• Grants and legislative strategies
• Incubation/Acceleration services
• Intellectual property assessment, acquisition, management and litigation
• IPOs/capital markets
• Patent and IT licensing and partnering
• Research and development agreements
• Reimbursement
• Strategic Advisory/Mergers & acquisitions
• Tax credit issues on research and development
• Venture capital

Our service can expand worldwide or contract to a local level, as required, from the laboratory and startup, to corporate governance, initial public offerings and beyond. That’s our commitment to you.

Insights

Fund-raising document landscape in USA, Germany and Singapore

July 14, 2022

Singapore: The authors, from Dentons’ firms in Singapore and Germany, seek to provide a cross-border comparison of equity-related transactions documents often used in fund-raising transactions in USA, Germany and Singapore. The authors hope this can provide initial guidance to investors and founders of early-stage entities to better understand the legal documentation involved in an investment transaction in each of these countries.

BIS imposes new emerging technology controls on certain software and related technology designed for nucleic acid assemblers and synthesizers

October 13, 2021

United States: BIS imposes new emerging technology controls on certain software and related technology designed for nucleic acid assemblers and synthesizers.

Scammed or hacked? Overview of common fraud techniques and the corporate response playbook (in Japanese)

June 11, 2021

Singapore: Scams and cyber attacks – it can happen to any corporate entity. Nobody is immune to scams and cyber-attacks. With the increase in scammers’ levels of sophistication, their targets have also increased in scale. Scammers even routinely target multinational corporates and banks which have far more robust defences and highly trained personnel than the average SME. As such, the authors seek to suggest a quick response playbook that companies can consider adopting and for determining their responses during a time-sensitive period when faced with such issues.

View all insights for Biotechnology Companies

News and Events

Recent Press Releases

Dentons welcomes Rick Pawluk as a partner in the Corporate group in Calgary

February 18, 2025

Dentons, Canada’s Global Law Firm, is pleased to announce the arrival of Rick Pawluk as a partner in the Corporate group in Calgary.

Dentons Paris advises Bpifrance Large Venture in the new funding round of Aqemia

December 12, 2024

Dentons Paris has advised Bpifrance Large Venture in the new $38 million funding round of Aqemia, bringing the total funds raised by the Paris-based techbio to over $100 million since its inception. Led by Cathay Innovation, the funding round also saw renewed participation from Aqemia’s historic investors, Wendel Growth, Eurazeo, Elaia, and Bpifrance Large Venture.

Dentons advises Bpifrance Large Venture in second round of financing of Aqemia of 30 million euros

February 6, 2024

Dentons Paris accompanied Bpifrance Large Venture in a new round of financing of Aqemia of 30 million euros that completes a 30-million euros fund raising carried out last year, bringing the total amount of its Series A to 60 million euros.

View all press releases for Biotechnology Companies